Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.

T.S. Waddell, I. Chau, C. Peckitt, D. Gonzalez, A. Wotherspoon, B. Patel, G.W. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T.D.L. Crosby, F.Y. Coxon, D. Smith, J.S. Waters, T. Iveson, S. Falk, S. Slater, A.F.C. Okines, D. Cunningham

Research output: Contribution to conferenceOther

Original languageEnglish
Publication statusPublished - 20 May 2014

Cite this

Waddell, T.S. ; Chau, I. ; Peckitt, C. ; Gonzalez, D. ; Wotherspoon, A. ; Patel, B. ; Middleton, G.W. ; Wadsley, J. ; Ferry, D. ; Mansoor, W. ; Crosby, T.D.L. ; Coxon, F.Y. ; Smith, D. ; Waters, J.S. ; Iveson, T. ; Falk, S. ; Slater, S. ; Okines, A.F.C. ; Cunningham, D. / Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.
@conference{9c54d225adbd4299b4dbbe0a973618eb,
title = "Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.",
author = "T.S. Waddell and I. Chau and C. Peckitt and D. Gonzalez and A. Wotherspoon and B. Patel and G.W. Middleton and J. Wadsley and D. Ferry and W. Mansoor and T.D.L. Crosby and F.Y. Coxon and D. Smith and J.S. Waters and T. Iveson and S. Falk and S. Slater and A.F.C. Okines and D. Cunningham",
year = "2014",
month = "5",
day = "20",
language = "English",

}

Waddell, TS, Chau, I, Peckitt, C, Gonzalez, D, Wotherspoon, A, Patel, B, Middleton, GW, Wadsley, J, Ferry, D, Mansoor, W, Crosby, TDL, Coxon, FY, Smith, D, Waters, JS, Iveson, T, Falk, S, Slater, S, Okines, AFC & Cunningham, D 2014, 'Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.'.

Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma. / Waddell, T.S.; Chau, I.; Peckitt, C.; Gonzalez, D.; Wotherspoon, A.; Patel, B.; Middleton, G.W.; Wadsley, J.; Ferry, D.; Mansoor, W.; Crosby, T.D.L.; Coxon, F.Y.; Smith, D.; Waters, J.S.; Iveson, T.; Falk, S.; Slater, S.; Okines, A.F.C.; Cunningham, D.

2014.

Research output: Contribution to conferenceOther

TY - CONF

T1 - Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.

AU - Waddell, T.S.

AU - Chau, I.

AU - Peckitt, C.

AU - Gonzalez, D.

AU - Wotherspoon, A.

AU - Patel, B.

AU - Middleton, G.W.

AU - Wadsley, J.

AU - Ferry, D.

AU - Mansoor, W.

AU - Crosby, T.D.L.

AU - Coxon, F.Y.

AU - Smith, D.

AU - Waters, J.S.

AU - Iveson, T.

AU - Falk, S.

AU - Slater, S.

AU - Okines, A.F.C.

AU - Cunningham, D.

PY - 2014/5/20

Y1 - 2014/5/20

M3 - Other

ER -